Pfizer (PFE) Given Neutral Rating at Jefferies Group

Jefferies Group reaffirmed their neutral rating on shares of Pfizer (NYSE:PFE) in a research report released on Monday. The firm currently has a $39.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on the company. JPMorgan Chase set a $42.00 price target on Pfizer and gave the stock a buy rating in a research note on Tuesday, May 8th. DZ Bank reissued a sell rating on shares of Pfizer in a research note on Thursday, May 3rd. Morningstar set a $43.50 price target on Pfizer and gave the stock a buy rating in a research note on Wednesday, May 2nd. BMO Capital Markets decreased their price target on Pfizer from $43.00 to $42.00 and set an outperform rating for the company in a research note on Wednesday, May 2nd. Finally, ValuEngine cut Pfizer from a buy rating to a hold rating in a research note on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $40.08.

Shares of Pfizer opened at $35.71 on Monday, according to Marketbeat. The firm has a market cap of $212.46 billion, a P/E ratio of 13.48, a P/E/G ratio of 1.77 and a beta of 0.89. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45. Pfizer has a 12 month low of $35.64 and a 12 month high of $35.80.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the prior year, the business earned $0.69 EPS. The firm’s revenue was up 1.0% on a year-over-year basis. equities analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, May 10th. This represents a $1.36 annualized dividend and a dividend yield of 3.81%. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other news, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. In the last 90 days, insiders sold 380,349 shares of company stock valued at $13,829,340. Insiders own 0.06% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Security Asset Management lifted its holdings in shares of Pfizer by 6.1% during the fourth quarter. Security Asset Management now owns 22,827 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 1,317 shares during the last quarter. Waldron LP raised its position in Pfizer by 6.0% during the fourth quarter. Waldron LP now owns 23,785 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 1,341 shares during the period. Community Financial Services Group LLC raised its position in Pfizer by 0.6% during the fourth quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock valued at $7,856,000 after buying an additional 1,375 shares during the period. TCI Wealth Advisors Inc. raised its position in Pfizer by 2.0% during the fourth quarter. TCI Wealth Advisors Inc. now owns 71,284 shares of the biopharmaceutical company’s stock valued at $2,582,000 after buying an additional 1,375 shares during the period. Finally, Banced Corp raised its position in Pfizer by 5.4% during the fourth quarter. Banced Corp now owns 26,667 shares of the biopharmaceutical company’s stock valued at $965,000 after buying an additional 1,376 shares during the period. 71.65% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply